results good this is going to fly, page-23

bluebells,

The 13 people dropping out of the 250mg dosage would obviously affect the result of that group, but it doesn't mean that that group have shown improvement with PI-88. The 250mg group had an increased chance of cancer recurring, compared to the control group (those who received no treatment at all).

Whilst it's good news that the fda has given pgl the knod to go onto phase 3, It doesn't mean that the drug is effective.

If you had three groups of 50 people, and gave them no treatment at all, it is most likely that each group would have different amounts of disease recurrance.

The fact is that one groups doseage of PI-88 increased their chances of getting cancer (& one groups doseage of PI-88 degreased their chances of getting cancer).

The patient group was too small, & the results too mixed, to declare that efficacy has been confirmed, imho. The larger phase 3 trial is required to do that.

Best wishes